Hidradenitis Suppurativa (HS) research hub
8 indexed studies · 5 currently recruiting
- recruitingPhase II and Phase III (Integrated)
Lunsayil LTE: An extension trial assessing long-term spesolimab treatment in patients with Hidradenitis Suppurativa (HS)
This study is looking at a new medicine called spesolimab for a skin condition called Hidradenitis Suppurativa, or HS. It's an extension study, meaning some people might have tried it before. Researchers want to see how safe and effective it is over a longer time.
Spain · Slovakia · France - recruitingTherapeutic confirmatory (Phase III)
A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of subcutaneous sonelokimab in adult participants with moderate to severe hidradenitis suppurativa (M1095-HS-301)
This study is testing a new medicine, sonelokimab, for adults with moderate to severe hidradenitis suppurativa (HS). It compares sonelokimab to a dummy treatment (placebo) to see if it improves HS symptoms and is safe to use.
Norway · Italy · Poland - recruitingTherapeutic confirmatory (Phase III)
A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of subcutaneous sonelokimab in adult participants with moderate to severe hidradenitis suppurativa (M1095-HS-302)
This study is testing a new medicine, sonelokimab, for adults with moderate to severe hidradenitis suppurativa (HS). It compares the new medicine to a dummy treatment (placebo) to see if it's safe and helps improve HS over 16 weeks.
Netherlands · Slovakia · Czechia - recruitingTherapeutic exploratory (Phase II)
Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients with Moderate to Severe Hidradenitis Suppurativa (LOTUS)
This study is testing a new medicine called AVTX-009 for a skin condition called hidradenitis suppurativa (HS). We want to see if it helps reduce painful lumps and spots, and if it's safe to use. Half the people will get the new medicine and half will get a dummy medicine.
France · Italy · Bulgaria - active not recruitingPHASE2
A Study With CIT-013 in HS Patients
This study is testing a new medicine called CIT-013 for adults with Hidradenitis Suppurativa (HS), a skin condition. Researchers want to see if CIT-013 helps reduce HS symptoms and if it's safe. It's a Phase 2 trial comparing different doses of CIT-013 to a dummy medicine.
Canada · Germany · Netherlands - recruitingPHASE3
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
This study is for people who have already taken part in certain Incyte povorcitinib trials for Hidradenitis Suppurativa (HS) and found the treatment helpful. It allows them to continue receiving the study drug if their doctor agrees it's safe and beneficial.
United States · Argentina · Australia - authorisedTherapeutic confirmatory (Phase III)
A double-blind, double-dummy, parallel group, multicenter Phase 3 extension study evaluating the long-term safety and efficacy of 2 doses of remibrutinib in adult participants with moderate to severe hidradenitis suppurativa
This study is looking at a new medicine called remibrutinib for adults with moderate to severe hidradenitis suppurativa (HS). It's a long-term study checking how safe and effective this medication is. We want to see if it causes side effects and helps improve HS.
Portugal · Greece · Germany - active not recruitingPHASE3
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
This study looks at a new medicine called Povorcitinib for moderate to severe hidradenitis suppurativa (HS). It's for people who have already finished an earlier study. We want to see how safe and effective it is over a longer time.
United States · Australia · Austria